<DOC>
	<DOCNO>NCT02318901</DOCNO>
	<brief_summary>There two phase II cohorts pembro plus trastuzumab : one cohort patient unresectable HER2 overexpressing gastric GEJ cancer , cohort patient HER2 overexpressing metastatic breast cancer ( MBC ) . The pembro plus ado-trastuzumab emtansine phase II arm patient HER2 overexpressing MBC . There two phase II cohorts pembro plus cetuximab : one cohort patient HNSCC , cohort patient K-ras , B-raf , N-ras wildtype metastatic CRC .</brief_summary>
	<brief_title>Pembrolizumab Monoclonal Antibody Therapy Advanced Cancer</brief_title>
	<detailed_description>Pembrolizumab 2mg/kg administer intravenously 30 minute every 3 week . Pembrolizumab infuse prior start assign monoclonal antibody ( Mab ) arm . . Dosing Mab arm begin follow : Arm 1 : Cycle length 21 day . Intravenous ( i.v . ) trastuzumab 6 mg/kg day 1 every 21 day . Arm 2 : Cycle length 21 day . i.v . ado-trastuzumab emtansine 3.6 mg/kg day 1 every 21 day . Arm 3 : Cycle length 21 day . i.v . cetuximab 400 mg/m2 cycle 1 day 1 , i.v . cetuximab 250 mg/m2 day 8 . Each subsequent cycle i.v . cetuximab 250 mg/m2 day 1 8 every 21 day .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>1 . Patient definitive histologically cytologically confirm unresectable metastatic solid tumor . 2 . Patient one tumor measurable define RECIST 1.1 CT scan ( PET/CT , patient allergic CT contrast medium ) . 3 . Patients enrol one treatment arm trial . 4 . The investigator select appropriate treatment arm patient follow requirement : ( ) Patients prior progression intolerance specific Mab enrol arm Mab plus pembro , ( b ) The Mab arm select must consider standard care list NCCN guideline ( www.nccn.org ) cancer type . For Arm 1 , patient HER2 overexpressing MBC eligible maintenance trastuzumab allow taxane plus trastuzumab plus pertuzumab combination therapy . 5 . Have recover acute toxicity prior treatment : 1 . &gt; 3 week must elapse since receive investigational agent . 2 . &gt; 2 week must elapse since receive radiotherapy , ≥ 3 week 5 halflives whichever shorter treatment cytotoxic biologic agent ( ≥ 6 week mitomycin nitrosoureas ) . Chronic treatment noninvestigational gonadotropinreleasing hormone analog hormonal supportive care permit . 6 . Patient adequate biological parameter demonstrate follow blood count time screening : 7 . Absolute neutrophil count ( ANC ) &gt; 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 9 g/dL . 8 . Serum creatinine ≤2.0 , total bilirubin ≤ 2 mg/dL , AST/ALT ≤ 5 time upper limit normal ( ULN ) range 9 . Thyroid stimulate hormone ( TSH ) within institutional normal limit . If TSH upper limit normal range , free T4 within institutional normal limit acceptable . 10 . Persistent prior systemic therapy nonhematologic AE grade ≥ 2 ( except alopecia correctable electrolyte abnormality supplementation ) 11 . Patient Karnofsky performance status ( KPS ) ≥ 70 . 12 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 30 day follow last dose study drug , must negative urine serum pregnancy test within 2 week prior begin treatment trial . Inclusion criterion Phase II : 1 . Patients must unresectable HER2 overexpressing gastric GEJ cancer enrol Cohort 1 pembro plus trastuzumab phase II portion . 2 . Patients must HER2 overexpressing MBC enrol Cohort 2 pembro plus trastuzumab phase II portion . 3 . Patients must HER2 overexpressing MBC enrol pembro plus adotrastuzumab emtansine phase II portion . 4 . Patients must HNSCC enrol Cohort 1 pembro plus cetuximab phase II portion . 5 . Patients must Kras , Braf , Nras wildtype CRC enrol Cohort 2 pembro plus cetuximab phase II portion . 1 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 . 2 . Serious nonhealing wound , ulcer , bone fracture . 3 . Patient known brain metastasis , unless previously treat wellcontrolled least 1 month ( define clinically stable , edema , steroid stable 2 scan least 4 week apart ) . 4 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 5 . Patient know active infection HIV , hepatitis B , hepatitis C ( patient NOT require test presence virus prior therapy protocol ) . 6 . Requiring daily corticosteroid dose ≥ 10 mg prednisone equivalent per day . 7 . Patient undergone major surgery , diagnostic surgery ( e.g. , surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 8 . Patient history allergy hypersensitivity study drug excipients , patient exhibit event outline Contraindication Special Warnings Precautions section product comparator SmPC Prescribing Information . 9 . Patient serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity . 10 . Patient receive anticancer therapy participation trial . 11 . Prior treatment pembro . Receipt PD1 inhibitor PDL1 inhibitor allow . 12 . Active prior document autoimmune disease require systemic treatment within past 2 year . Exclusion Criteria phase II portion : 1 . Patients history one primary cancer , exception : ) curatively resect nonmelanomatous skin cancer ; b ) curatively treated cervical carcinoma insitu ; c ) primary solid tumor treat curative intent know active disease present treatment administer 2 year prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>